ZP6590 — EU research guide.
ZP6590 is Zealand Pharma's investigational long-acting GIP receptor agonist, designed not as a standalone obesity drug but as a co-formulation partner that boosts the effect of GLP-1 medicines like semaglutide.
What is ZP6590?
In preclinical models, ZP6590 has little weight-loss effect alone but substantially amplifies the weight loss produced by GLP-1 monotherapy when combined — the same ‘dual agonism’ logic behind tirzepatide, but as two separate co-dosed molecules instead of one hybrid peptide.
What does the research show?
As of Zealand Pharma's early-2026 pipeline disclosures, ZP6590 is Phase 1-ready for obesity, positioned as a future combination partner alongside the company's more advanced amylin analogue, petrelintide.
EU legal status
Not approved anywhere; a very early-stage, single-sponsor investigational candidate with no legitimate research-peptide supply route.
Molecular information
Pharmacokinetics
GLP-1/GIP compounds across EU suppliers
COA-verified EU vendors · Updated monthly